查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984024

人工智慧在製藥市場的應用：按組件、技術、治療領域、應用、部署模式和最終用戶分類——2026年至2032年全球市場預測

Artificial Intelligence in Pharmaceutical Market by Component, Technology, Therapeutic Area, Applications, Deployment Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，醫藥產業的人工智慧 (AI) 市場價值為 200.8 億美元，預計到 2026 年將成長至 255.4 億美元，複合年成長率為 27.68%，到 2032 年將達到 1,111.3 億美元。

主要市場統計數據
基準年 2025 200.8億美元
預計年份：2026年 255.4億美元
預測年份 2032 1111.3億美元
複合年成長率 (%) 27.68%

策略實施：概述人工智慧如何改變藥物研究、臨床操作、監管流程、生產工作流程和商業策略。

人工智慧不再是製藥營運中的實驗性輔助手段，而是涵蓋藥物發現、臨床開發、監管策略、生產營運和商業性決策等各環節的關鍵策略能力。在這種應用模式下，人工智慧不再只是一系列技術的集合，而是一股系統級力量，它重塑了藥物整個生命週期中的知識創造、自動化決策和風險管理。因此，相關人員需要從多個觀點看待人工智慧：將其視為藥物發現中假設產生的加速器、患者篩選和臨床試驗最佳化的精準工具、監管合規的分析引擎，以及支撐供應鏈韌性的營運驅動力。

詳細概述了透過人工智慧重新定義藥物發現、臨床試驗設計、監管參與、生產製造和病人參與的變革性技術和組織變革。

製藥業正經歷一場由技術突破、組織思維轉變和外部政策影響共同驅動的變革。在技術水準，模型架構、訓練方法和領域自適應演算法的進步正在拓展自動化和預測的邊界。卷積類神經網路、生成對立網路、循環神經網路和變壓器等深度學習創新技術正日益與監督學習、無監督學習和強化學習等可操作的機器學習方法相結合，以解決複雜的生物醫學問題。同時，影像分割、醫學影像應用和目標檢測等電腦視覺技術正在為診斷和臨床前分析開闢新的途徑，而自然語言處理則能夠透過情感分析、語音辨識和文字探勘等技術，從臨床記錄、監管申報文件和文獻中提取可操作的見解。

對 2025 年美國實施的關稅措施對人工智慧驅動的藥品供應鏈、跨境採購、製造投入和合作模式的累積影響進行重點分析。

2025年推出的關稅環境進一步增加了人工智慧驅動型製藥企業在採購、供應鏈規劃和跨國合作方面的複雜性。影響硬體進口、試劑採購、臨床設備和軟體許可的關稅措施可能會對整個生態系統產生連鎖反應。例如，提高專用運算硬體和實驗室設備的關稅可能會增加本地部署的總擁有成本，從而使能夠外包運算風險的雲端解決方案獲得財務優勢。相反，針對特定SaaS模式或捆綁解決方案的關稅可能會促使採購方向轉向模組化架構和在地化服務模式。

整合細分洞察，解釋人工智慧在製藥業的應用和價值創造是如何由組件、技術系列、治療領域、應用領域、部署模式和最終用戶畫像共同決定的。

要了解人工智慧將在製藥業的哪些領域以及如何創造價值，必須整合影響部署模式和結果的多個細分維度。按組件分類，市場由“服務”和“軟體”組成，“服務”又可細分為“託管服務”和“專業服務”，而“軟體”則包括臨床試驗管理軟體、診斷軟體、藥物發現平台、法規遵從工具和供應鏈管理軟體。這種組件層面的觀點表明，在實際部署中，軟體平台通常與實施和託管支援相結合，以確保效能符合監管標準並維持營運連續性。

全面深入的區域分析，比較美洲、歐洲、中東、非洲和亞太地區的策略促進因素、監管環境、投資趨勢、基礎設施發展和商業性採用模式。

區域趨勢正顯著影響人工智慧在整個醫藥價值鏈中的應用和推廣，美洲、歐洲、中東、非洲和亞太地區呈現出截然不同的模式。在美洲，穩健的私營部門投資環境、先進的雲端基礎設施和成熟的創投生態系統正在加速平台開發和商業部署。同時，特定司法管轄區的監管指導正轉向基於結果的檢驗，並建立更清晰的醫療設備軟體框架。這為擁有快速迭代開發能力和強大證據生成能力的公司創造了有利環境。

本報告提供企業洞察，重點在於推動醫藥創新的關鍵人工智慧參與者的競爭定位、夥伴關係策略、產品和服務組合、平台差異化和市場進入方式。

醫藥人工智慧生態系統中的企業行為展現出清晰的策略模式。這些模式包括：平台提供者投資於端到端的產品套件；專注於特定高價值應用場景的專業演算法開發人員；將領域專業知識與可擴展實施方案相結合的系統整合商；以及將人工智慧能力融入外包開發服務的合約研究組織（CRO）。主要企業透過檢驗的數據資產、規範的工作流程以及降低生命科學客戶整合摩擦的能力來脫穎而出。

為高階主管提供可操作的策略建議，以加速負責任的人工智慧應用，優先考慮管治、人才發展、生態系統夥伴關係、平台選擇和跨部門監管合規。

致力於加速負責任且策略性地應用人工智慧的產業領導者應將管治、人才、技術和夥伴關係關係有機地整合起來。首先，應建立跨職能管治，明確模型開發、檢驗、部署和監控的職責。此管治結構應整合法律、監管、臨床和技術等相關人員，並制定標準化的檢驗通訊協定和審計追蹤，以滿足監管機構和內部風險管理部門的要求。同時，應投資於人才發展項目，將產業專長與資料科學技能結合。輪調計畫、將資料科學家長期安置在治療團隊中，以及策略性地招募精通監管的機器學習工程師，都能縮短回饋週期，並提高演算法與臨床目標的契合度。

透明的調查方法，說明了資料來源、相關人員訪談、與技術分類系統的一致性、治療領域的映射、檢驗過程以及用於得出結論的分析框架。

本報告的結論和見解基於多方面的研究方法，結合了第一手和第二手研究、專家訪談以及針對技術和治療領域的分類，確保其適用於任何決策情境。資料收集包括與涵蓋製藥公司、生物技術公司、合約研究組織 (CRO)、臨床研究人員、監管專家和技術供應商等跨學科相關人員的結構化討論，檢驗了實際限制、推薦的檢驗策略和部署模型。第二手資訊來源包括同行評審文獻、監管指導文件、醫療設備軟體標準以及可作為模型架構和檢驗方法參考的公開技術資訊。

簡潔的結論整合了對研發、臨床營運、監管策略、商業部署和供應鏈韌性的見解，同時強調了管治、技能和協作的必要性。

這些分析綜合起來，凸顯了一個戰略現實：人工智慧 (AI) 如今已成為製藥公司提升研發效率、簡化臨床試驗、加強監管合規性以及最佳化供應鏈韌性的基礎能力。在這個時代，成功的關鍵不在於盲目追逐每項技術創新，而是將 AI 投資與臨床和監管的優先事項及規範相契合，並建立嚴格的檢驗方法和穩健的營運管治。那些將特定領域模型開發與提供互補數據、實驗室自動化和實施專業知識的夥伴關係相結合的組織，將能夠更快地從原型階段過渡到實際營運階段。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 醫藥市場：依成分分類

  • 服務
    • 託管服務
    • 專業服務
  • 軟體
    • 臨床試驗管理軟體
    • 診斷軟體
    • 藥物發現平台
    • 監理合規工具
    • 供應鏈管理軟體

第9章 醫藥市場：依技術分類

  • 電腦視覺
    • 影像分割
    • 醫學影像
    • 目標偵測
  • 深度學習
    • 卷積類神經網路
    • 生成性衝突網路
    • 遞迴神經網
    • 變壓器
  • 機器學習
    • 強化學習
    • 監督式學習
    • 無監督學習
  • 自然語言處理
    • 情緒分析
    • 語音辨識
    • 文字探勘
  • 機器人流程自動化

第10章：醫藥市場：依治療領域分類

  • 心血管疾病
  • 免疫學
  • 感染疾病
  • 代謝性疾病
  • 神經病學
  • 腫瘤學
  • 呼吸系統疾病

第11章 醫藥市場：依應用領域分類

  • 臨床試驗
    • 臨床數據管理
    • 病患招募
    • 預測分析
    • 基於風險的監測
  • 藥物發現
    • 藥物發現
    • 最終模型的檢驗
    • 先導藥物最適化
    • 目標選擇
  • 個性化醫療保健
    • 生物標記發現
    • 基因組分析
    • 精準醫療發展
  • 供應鏈管理
    • 需求預測
    • 庫存管理
    • 物流最佳化

第12章 醫藥市場：依開發類型分類

  • 基於雲端的
  • 現場

第13章 醫藥市場：依最終用戶分類

  • 學術和研究機構
  • 合約研究組織（CRO）
  • 製藥和生物技術公司

第14章 醫藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 醫藥市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 藥品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國醫藥市場

第18章：中國醫藥市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AiCure, LLC
  • Aspen Technology Inc.
  • Atomwise Inc.
  • BenevolentAI SA
  • BioSymetrics Inc.
  • BPGbio Inc.
  • Butterfly Network, Inc.
  • Cloud Pharmaceuticals, Inc.
  • Cyclica by Recursion Pharmaceuticals, Inc.
  • Deargen Inc.
  • Deep Genomics Incorporated
  • Deloitte Touche Tohmatsu Limited
  • Euretos Services BV
  • Exscientia PLC
  • Insilico Medicine
  • Intel Corporation
  • International Business Machines Corporation
  • InveniAI LLC
  • Isomorphic Labs Limited
  • Microsoft Corporation
  • Novo Nordisk A/S
  • NVIDIA Corporation
  • Oracle Corporation
  • SANOFI WINTHROP INDUSTRIE
  • Turbine Ltd.
  • Viseven Europe OU
  • XtalPi Inc.
Product Code: MRR-A6768A62EE00

The Artificial Intelligence in Pharmaceutical Market was valued at USD 20.08 billion in 2025 and is projected to grow to USD 25.54 billion in 2026, with a CAGR of 27.68%, reaching USD 111.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.08 billion
Estimated Year [2026] USD 25.54 billion
Forecast Year [2032] USD 111.13 billion
CAGR (%) 27.68%

A strategic introduction outlining how artificial intelligence is reshaping pharmaceutical research, clinical operations, regulatory pathways, manufacturing workflows, and commercial strategies

Artificial intelligence is no longer an experimental adjunct in pharmaceutical workstreams; it has become an integral strategic capability that touches discovery science, clinical development, regulatory strategy, manufacturing operations, and commercial decision-making. This introduction frames AI not merely as a set of technologies but as a system-level force reshaping how knowledge is generated, decisions are automated, and risks are managed across the lifecycle of medicines. Stakeholders must therefore view AI through multiple lenses: as an accelerant for hypothesis generation in drug discovery, as a precision tool for patient identification and trial optimization, as an analytics engine for regulatory compliance, and as an operational enabler for supply chain resilience.

To navigate this environment, leaders must appreciate three converging dynamics. First, advances in compute, data infrastructure, and model architectures are broadening the range of tractable problems. Second, the maturation of domain-specific platforms and validated workflows is lowering integration friction for research and clinical teams. Third, regulatory and ethical expectations are co-evolving with capabilities, increasing the importance of reproducibility, explainability, and robust validation. As a result, AI adoption in pharmaceuticals is increasingly driven by outcome-oriented deployments that emphasize measurable improvements in cycle time, quality, and patient-centricity rather than technology for its own sake.

This introductory analysis sets the stage for deeper examination by emphasizing practical implications for R&D leaders, clinical operations directors, regulatory strategists, manufacturing heads, and commercial executives. It establishes the imperative for cross-functional governance, a clear technology- and data-integration roadmap, and an investment posture that balances platform development with targeted proof-of-concept initiatives. In short, organizations that align technical capability with clinical and regulatory objectives are positioned to capture disproportionate value as AI transitions from novelty to operational backbone.

A detailed synthesis of transformative technological and organizational shifts that are redefining drug discovery, trial design, regulatory interactions, manufacturing, and patient engagement through AI

The pharmaceutical landscape is undergoing transformative shifts driven by technological breakthroughs, shifting organizational mindsets, and external policy influences. At the technology level, advances in model architectures, training regimes, and domain-adapted algorithms are expanding the frontier of what can be automated and predicted. Deep learning innovations in convolutional neural networks, generative adversarial networks, recurrent neural networks, and transformers are increasingly coupled with pragmatic machine learning approaches such as supervised and unsupervised learning plus reinforcement learning to address complex biomedical problems. In parallel, computer vision capabilities including image segmentation, medical imaging applications, and object detection are unlocking new modalities for diagnostics and preclinical assay analysis, while natural language processing is enabling extraction of actionable insights from clinical notes, regulatory submissions, and literature through techniques such as sentiment analysis, speech recognition, and text mining.

Organizationally, there is a clear shift from isolated proofs of concept to scaled deployments that integrate software and service offerings. Component-level segmentation illustrates that software domains-ranging from clinical trial management platforms and diagnostic tools to drug discovery platforms, regulatory compliance tools, and supply chain management solutions-are being complemented by services ecosystems that include managed and professional services. This integration of services and software is accelerating time-to-value by combining technical implementation with domain expertise. Simultaneously, application domains such as clinical trials, drug discovery, personalized healthcare, and supply chain optimization are maturing; clinical trial automation is extending into patient recruitment, clinical data management, predictive analytics, and risk-based monitoring, while drug discovery workflows are embracing computational drug design, lead optimization, target selection, and end-model validation.

These shifts are also reshaping talent and partnership strategies. Life sciences organizations are investing in cross-disciplinary teams that combine biomedical scientists, data engineers, and regulatory specialists. Contract research organizations and technology vendors are forming deeper alliances with pharmaceutical companies to co-develop validated workflows and to ensure reproducibility. Taken together, these technical and organizational transformations are creating a new competitive dynamic where speed, rigor, and regulatory-aligned validation are the primary differentiators.

A focused analysis of the cumulative effects of United States tariff measures enacted in 2025 on AI-enabled pharmaceutical supply chains, cross-border sourcing, manufacturing inputs, and collaboration models

The tariff landscape introduced in 2025 has introduced additional complexity into procurement, supply chain planning, and cross-border collaboration for AI-enabled pharmaceutical operations. Tariff measures that affect hardware imports, reagent sourcing, clinical instrumentation, and software licensing can create ripple effects across the ecosystem. For example, increases in duties on specialized computing hardware or laboratory instrumentation raise the total cost of ownership for on-premises deployments and may tilt the economics in favor of cloud-based solutions where compute risks can be externalized. Conversely, tariffs that target certain software-as-a-service models or bundled solutions can shift procurement preferences toward modular architectures and localized service models.

Beyond direct cost impacts, tariffs affect supplier selection and sourcing strategies. Organizations respond by diversifying supplier bases, accelerating qualification of alternative vendors, and re-evaluating regional manufacturing footprints to mitigate exposure to trade policy shifts. These adjustments often influence timelines for validation and regulatory filings, because change controls associated with new suppliers or different equipment can introduce additional documentation burdens. In addition, tariffs can influence investment decisions in nearshoring or reshoring initiatives, where companies seek to reduce cross-border dependencies for critical components or biologics manufacturing inputs.

Moreover, tariffs have implications for collaborative research and data-sharing arrangements across borders. Increased customs scrutiny and shifting import regimes can complicate the transport of biological samples, specialized reagents, and equipment essential for collaborative trials. For multinational programs, sponsors may need to redesign logistics corridors, re-assess third-party provider contracts, and update risk registers to reflect tariff-induced delays. In response, savvy organizations are prioritizing supply chain visibility, multi-source qualification, and contractual flexibility as part of their operational resilience programs. While tariffs do not alter the scientific feasibility of AI applications, they meaningfully affect the operational pathways through which those applications are deployed and scaled.

Integrated segmentation insights explaining how components, technology families, therapeutic focus areas, application domains, deployment models, and end-user profiles jointly determine AI uptake and value creation in pharma

Understanding where and how AI generates value in pharmaceuticals requires an integrated view of multiple segmentation axes that together shape adoption patterns and outcomes. Based on Component, the landscape comprises Services and Software where Services splits into Managed Services and Professional Services and Software includes clinical trial management software, diagnostic software, drug discovery platforms, regulatory compliance tools, and supply chain management software. This component-level view clarifies that practical deployments frequently combine software platforms with implementation and managed support to ensure regulatory-grade performance and operational continuity.

Based on Technology, adopters must evaluate capabilities across computer vision, deep learning, machine learning, natural language processing, and robotic process automation; within these families there are important sub-specializations such as image segmentation, medical imaging, and object detection for computer vision, convolutional neural networks, generative adversarial networks, recurrent neural networks, and transformers for deep learning, and reinforcement learning, supervised learning, and unsupervised learning for machine learning, alongside sentiment analysis, speech recognition, and text mining for NLP. The multiplicity of approaches underscores the need for a technology taxonomy that maps each method to specific use cases and validation requirements.

Based on Therapeutic Area, AI initiatives often align with clinical priority and data maturity across cardiovascular diseases, immunology, infectious diseases, metabolic diseases, neurology, oncology, and respiratory diseases. Disease biology, endpoint definability, and data availability vary across these areas, which in turn affects algorithmic approachability and regulatory scrutiny. Based on Applications, deployment domains include clinical trials, drug discovery, personalized healthcare, and supply chain management with clinical trials subdividing into clinical data management, patient recruitment, predictive analytics, and risk-based monitoring, while drug discovery encompasses drug design, end-model validation, lead optimization, and target selection and personalized healthcare covers biomarker discovery, genomic profiling, and precision medicine development and supply chain management focuses on demand forecasting, inventory management, and logistics optimization.

Based on Deployment Type, choices between cloud-based and on-premises architectures have implications for data governance, latency, and cost structure, and based on End User, the primary consumers of these solutions span academic and research institutions, contract research organizations, and pharmaceutical and biotechnology companies. The intersections among these segmentation axes create contextual trade-offs: for example, oncology discovery efforts may preferentially adopt deep learning generative models and on-premises deployments when patient-level privacy and validation are paramount, while supply chain optimization workstreams commonly leverage cloud-based machine learning and managed services to maximize elasticity and cross-site visibility. Therefore, segmentation-aware strategies are essential to align technical design, validation planning, procurement strategy, and organizational capability development.

Comprehensive regional insights comparing strategic drivers, regulatory landscapes, investment trends, infrastructure readiness, and commercial adoption patterns across Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a strong influence on how AI is adopted and scaled across the pharmaceutical value chain, with distinctive patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a robust private sector investment environment, advanced cloud infrastructure, and established venture ecosystems have accelerated platform development and commercial deployments, while regulatory guidance in certain jurisdictions has moved toward outcomes-based validation and clearer frameworks for software as a medical device. This creates a favorable environment for companies that combine rapid iteration with strong evidence-generation capabilities.

In Europe, Middle East & Africa, regulatory rigor and data protection regimes shape design and deployment choices, often increasing the emphasis on explainability, localized data residency, and formalized validation paths. National policy initiatives and pan-European collaborations have also fostered consortium-based models for data sharing that enable multicenter trials and federated learning approaches. Meanwhile in parts of the Middle East and Africa, infrastructural variability and nascent data ecosystems require bespoke implementation models and capacity-building partnerships.

Asia-Pacific presents a heterogeneous but highly dynamic set of conditions where strong manufacturing clusters, rapidly growing clinical trial activity, and sizable patient populations create compelling use cases for AI. Several markets in the region are advancing digital health policies and public-private partnerships that accelerate deployment of diagnostic and clinical decision-support tools. Importantly, regional supply chain integration, proximity to key hardware suppliers, and an expanding talent base make Asia-Pacific an attractive locus for both development and scaled implementation projects. Across all regions, local regulatory expectations, talent availability, data governance frameworks, and infrastructure maturity determine the optimal mix of cloud versus on-premises deployment and the most effective partnership models for vendors and sponsors alike.

Company insights emphasizing competitive positioning, partnership strategies, product and service portfolios, platform differentiation, and go-to-market approaches among leading AI players supporting pharmaceutical innovation

Company behavior in the AI-for-pharma ecosystem demonstrates distinct strategic archetypes, including platform providers that invest in end-to-end product suites, specialized algorithm developers focusing on narrow high-value use cases, systems integrators that bridge domain expertise with scalable implementation, and contract research organizations that embed AI capabilities into outsourced development services. Leading organizations are differentiating through validated data assets, regulatory-compliant workflows, and capabilities that reduce integration friction for life sciences customers.

Across supplier strategies, we observe three persistent patterns. The first is platform consolidation where vendors expand horizontally to offer clinical trial, discovery, and compliance modules that interoperate within a single architecture. The second is vertical specialization where niche players concentrate on a therapeutic or modality-specific problem-such as imaging in oncology or genomic profiling in personalized medicine-and achieve deep validation within that domain. The third pattern is partnership ecosystems where companies join forces to combine proprietary algorithms, clinical data, and laboratory automation in order to deliver regulated outcomes.

From a procurement perspective, pharmaceutical and biotechnology customers increasingly evaluate vendors on evidence of real-world performance, regulatory readiness, and post-deployment support capabilities, rather than on feature checklists alone. As a result, successful companies prioritize clinical validation studies, transparent model governance, and comprehensive professional or managed services to ensure sustained operational performance. Contracts reflect these expectations with outcomes-linked milestones, change-control provisions, and clear responsibilities for data stewardship and model maintenance.

Actionable strategic recommendations for executives to accelerate responsible AI adoption by prioritizing governance, talent development, ecosystem partnerships, platform selection, and regulatory alignment across functions

Industry leaders seeking to accelerate responsible and strategic AI adoption should pursue a coherent mix of governance, talent, technology, and partnership actions. Begin by establishing cross-functional governance that assigns clear accountability for model development, validation, deployment, and monitoring; governance structures should integrate legal, regulatory, clinical, and technical stakeholders and define standardized validation protocols and audit trails to satisfy regulators and internal risk functions. Simultaneously, invest in talent programs that blend domain expertise with data science skills; rotational programs, embedded data scientists within therapeutic teams, and strategic hiring of regulatory-savvy machine learning engineers will shorten feedback loops and improve the alignment of algorithms with clinical objectives.

On the technology front, prioritize modular architectures that balance the benefits of cloud-based scalability with the control afforded by on-premises deployments where privacy or latency constraints demand it. Adopt open and transparent model governance practices, including versioning, reproducibility tests, and clear explainability artifacts tied to clinical endpoints. In parallel, develop an ecosystem strategy that differentiates between capabilities to build internally and those best accessed through partnerships with academic centers, CROs, or specialized vendors. Structured collaborations with contract research organizations can accelerate trial execution, while alliances with diagnostic firms and lab automation providers can de-risk end-to-end implementation.

Finally, align procurement and contracting approaches with performance-based outcomes and continuous validation requirements. Include provisions for post-deployment monitoring, change management, and retraining cycles in vendor agreements. Taken together, these steps provide a pragmatic roadmap for leaders to scale AI responsibly while delivering measurable clinical and operational improvements.

A transparent research methodology describing data sources, stakeholder interviews, technology taxonomy alignment, therapeutic mapping, validation processes, and analytical frameworks used to generate conclusions

The conclusions and insights in this report are grounded in a multi-method research approach combining primary and secondary evidence, expert interviews, and a technology- and therapeutic-focused taxonomy to ensure applicability across decision contexts. Data collection included structured discussions with interdisciplinary stakeholders across pharmaceutical companies, biotechnology firms, contract research organizations, clinical investigators, regulatory specialists, and technology vendors to validate practical constraints, preferred validation strategies, and deployment models. Secondary inputs comprised peer-reviewed literature, regulatory guidance documents, standards for software as a medical device, and public technical disclosures that inform model architectures and validation practices.

Analytically, the work uses a taxonomy that maps component types, technology families, therapeutic priorities, application domains, deployment models, and end-user segments to observed adoption patterns and implementation risks. Validation exercises included cross-referencing interview findings with documented case studies and technology white papers, and applying scenario analysis to explore the operational consequences of supply chain disruptions and policy changes. Quality assurance measures involved iterative peer review, triangulation of evidence across sources, and explicit documentation of assumptions and limitations. This methodology ensures that recommendations are traceable to observable practices and that the analytical framework remains adaptable to evolving regulatory and technical developments.

A concise conclusion synthesizing implications for R&D, clinical operations, regulatory strategy, commercial deployment, and supply chain resilience while emphasizing governance, skills, and collaboration imperatives

The cumulative analysis underscores a singular strategic reality: artificial intelligence is now a foundational capability for pharmaceutical organizations that seek to improve R&D productivity, enhance clinical trial efficiency, strengthen regulatory compliance, and optimize supply chain resilience. Success in this era depends not on chasing every technical novelty but on disciplined alignment of AI investments with clinical and regulatory priorities, rigorous validation practices, and robust operational governance. Organizations that combine domain-focused model development with partnerships that supply complementary data, lab automation, and implementation expertise will move faster from prototype to production.

Moreover, the interplay between policy levers-such as tariffs and data governance regimes-and operational execution highlights the need for continuous risk assessment and adaptive sourcing strategies. Effective deployment requires a pragmatic mix of cloud and on-premises approaches informed by privacy constraints and latency considerations, and contracting models that emphasize outcomes and post-deployment stewardship. Ultimately, building sustained advantage with AI in pharmaceuticals is a multi-year endeavor that hinges on reproducibility, explainability, and the capacity to learn from real-world performance. Executives who prioritize these elements will be positioned to convert technical capability into measurable clinical and business results.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Intelligence in Pharmaceutical Market, by Component

  • 8.1. Services
    • 8.1.1. Managed Services
    • 8.1.2. Professional Services
  • 8.2. Software
    • 8.2.1. Clinical Trial Management Software
    • 8.2.2. Diagnostic Software
    • 8.2.3. Drug Discovery Platforms
    • 8.2.4. Regulatory Compliance Tools
    • 8.2.5. Supply Chain Management Software

9. Artificial Intelligence in Pharmaceutical Market, by Technology

  • 9.1. Computer Vision
    • 9.1.1. Image Segmentation
    • 9.1.2. Medical Imaging
    • 9.1.3. Object Detection
  • 9.2. Deep Learning
    • 9.2.1. Convolutional Neural Networks
    • 9.2.2. Generative Adversarial Networks
    • 9.2.3. Recurrent Neural Networks
    • 9.2.4. Transformers
  • 9.3. Machine Learning
    • 9.3.1. Reinforcement Learning
    • 9.3.2. Supervised Learning
    • 9.3.3. Unsupervised Learning
  • 9.4. Natural Language Processing
    • 9.4.1. Sentiment Analysis
    • 9.4.2. Speech Recognition
    • 9.4.3. Text Mining
  • 9.5. Robotic Process Automation

10. Artificial Intelligence in Pharmaceutical Market, by Therapeutic Area

  • 10.1. Cardiovascular Diseases
  • 10.2. Immunology
  • 10.3. Infectious Diseases
  • 10.4. Metabolic Diseases
  • 10.5. Neurology
  • 10.6. Oncology
  • 10.7. Respiratory Diseases

11. Artificial Intelligence in Pharmaceutical Market, by Applications

  • 11.1. Clinical Trials
    • 11.1.1. Clinical Data Management
    • 11.1.2. Patient Recruitment
    • 11.1.3. Predictive Analytics
    • 11.1.4. Risk-Based Monitoring
  • 11.2. Drug Discovery
    • 11.2.1. Drug Design
    • 11.2.2. End-Model Validation
    • 11.2.3. Lead Optimization
    • 11.2.4. Target Selection
  • 11.3. Personalized Healthcare
    • 11.3.1. Biomarker Discovery
    • 11.3.2. Genomic Profiling
    • 11.3.3. Precision Medicine Development
  • 11.4. Supply Chain Management
    • 11.4.1. Demand Forecasting
    • 11.4.2. Inventory Management
    • 11.4.3. Logistics Optimization

12. Artificial Intelligence in Pharmaceutical Market, by Deployment Type

  • 12.1. Cloud-Based
  • 12.2. On-Premises

13. Artificial Intelligence in Pharmaceutical Market, by End User

  • 13.1. Academic and Research Institutions
  • 13.2. Contract Research Organizations (CROs)
  • 13.3. Pharmaceutical & Biotechnology Companies

14. Artificial Intelligence in Pharmaceutical Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Artificial Intelligence in Pharmaceutical Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Artificial Intelligence in Pharmaceutical Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Artificial Intelligence in Pharmaceutical Market

18. China Artificial Intelligence in Pharmaceutical Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AiCure, LLC
  • 19.6. Aspen Technology Inc.
  • 19.7. Atomwise Inc.
  • 19.8. BenevolentAI SA
  • 19.9. BioSymetrics Inc.
  • 19.10. BPGbio Inc.
  • 19.11. Butterfly Network, Inc.
  • 19.12. Cloud Pharmaceuticals, Inc.
  • 19.13. Cyclica by Recursion Pharmaceuticals, Inc.
  • 19.14. Deargen Inc.
  • 19.15. Deep Genomics Incorporated
  • 19.16. Deloitte Touche Tohmatsu Limited
  • 19.17. Euretos Services BV
  • 19.18. Exscientia PLC
  • 19.19. Insilico Medicine
  • 19.20. Intel Corporation
  • 19.21. International Business Machines Corporation
  • 19.22. InveniAI LLC
  • 19.23. Isomorphic Labs Limited
  • 19.24. Microsoft Corporation
  • 19.25. Novo Nordisk A/S
  • 19.26. NVIDIA Corporation
  • 19.27. Oracle Corporation
  • 19.28. SANOFI WINTHROP INDUSTRIE
  • 19.29. Turbine Ltd.
  • 19.30. Viseven Europe OU
  • 19.31. XtalPi Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MANAGED SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MANAGED SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MANAGED SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PROFESSIONAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PROFESSIONAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PROFESSIONAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGULATORY COMPLIANCE TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGULATORY COMPLIANCE TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGULATORY COMPLIANCE TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY IMAGE SEGMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY IMAGE SEGMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY IMAGE SEGMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MEDICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MEDICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MEDICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OBJECT DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OBJECT DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OBJECT DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENERATIVE ADVERSARIAL NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENERATIVE ADVERSARIAL NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENERATIVE ADVERSARIAL NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RECURRENT NEURAL NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RECURRENT NEURAL NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RECURRENT NEURAL NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TRANSFORMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TRANSFORMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TRANSFORMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REINFORCEMENT LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REINFORCEMENT LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REINFORCEMENT LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY UNSUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY UNSUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY UNSUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SENTIMENT ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SENTIMENT ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SENTIMENT ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SPEECH RECOGNITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SPEECH RECOGNITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SPEECH RECOGNITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TEXT MINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TEXT MINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TEXT MINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY METABOLIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY METABOLIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RESPIRATORY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RESPIRATORY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PATIENT RECRUITMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PATIENT RECRUITMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PATIENT RECRUITMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PREDICTIVE ANALYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PREDICTIVE ANALYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PREDICTIVE ANALYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RISK-BASED MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RISK-BASED MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RISK-BASED MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END-MODEL VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END-MODEL VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END-MODEL VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TARGET SELECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TARGET SELECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TARGET SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENOMIC PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENOMIC PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENOMIC PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PRECISION MEDICINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PRECISION MEDICINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PRECISION MEDICINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEMAND FORECASTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEMAND FORECASTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEMAND FORECASTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY INVENTORY MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY INVENTORY MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY INVENTORY MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LOGISTICS OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LOGISTICS OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LOGISTICS OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ON-PREMISES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ON-PREMISES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ON-PREMISES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED